CA-GLOBALLOGIC
4.8.2022 05:32:14 CEST | Business Wire | Press release
GlobalLogic Inc. , a Hitachi Group Company and leader in Digital Engineering, today announced that its President and CEO Shashank Samant will be succeeded by the firm’s current Chief Operating Officer (COO) Nitesh Banga, who will become the new President and CEO effective October 1, 2022. Nitesh is a well-rounded and seasoned executive who has successfully worked across functions from Strategy, Go-To-Market, Engineering, and Operations while also launching similar businesses in the Japan market. Shashank will assume a new role as Chairman of the GlobalLogic Board, in addition to being the Executive Advisor to Mr. Toshiaki Tokunaga, the Head of Hitachi Digital Systems and Services (DSS) Sector. In this capacity, Shashank will continue to support the GlobalLogic business as well as advise on Hitachi Group's broader digital business growth strategy.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220803006014/en/
For more than a decade as CEO, Shashank led GlobalLogic through strong growth phases during which he oversaw several strategic acquisitions and digital capability expansion efforts. His leadership and expertise took the company from a group of elite software engineers to a global digital engineering leader, eventually becoming a part of the Hitachi Group.
“I am proud of the industry leading growth we achieved during my time as GlobalLogic’s CEO,” commented Shashank. “I believe that for organizations to continue to lead and succeed, their executive leadership must also evolve. Nitesh has proven throughout his career that he is a strong leader across both vision and execution. I am confident that he will set a successful course that will take GlobalLogic through its next major growth phases. I’m also very excited to continue supporting GlobalLogic in my new role as Chairman of the Board as well as to contribute to Hitachi Group’s digital business expansion and digital transformation acceleration.”
Since his arrival in 2018, Nitesh has led critical functions of GlobalLogic’s business. He contributed significantly to GlobalLogic’s noteworthy growth while also adeptly navigating the company through monumental challenges including the COVID-19 pandemic and the war in Ukraine.
Nitesh is a services industry veteran with diversified expertise ranging across Strategy, Business Development, Service Delivery, Operations, and Mergers and Acquisitions. He has adeptly run large-scale P&L organizations and has a deep understanding of Western and Eastern cultures, including Japan. Prior to joining GlobalLogic, he spent more than two decades at IT services and consulting firm Infosys.
“It’s an honor and great responsibility to lead GlobalLogic,” said Nitesh. “The passion, expertise, and deep commitment to our clients’ success demonstrated by our employees has created an invigorating, creative institution. As we enter our third decade, we have a unique opportunity to accelerate enterprise digital transformation backed by Hitachi’s incredible heritage, global reach, and trusted brand.”
“Since GlobalLogic joined the Hitachi Group, Shashank has made significant contributions to the growth of its entire digital business. I look forward to his continued strength in helping the Hitachi Group grow and transform through digital technology,” said Keiji Kojima, President and CEO of Hitachi, Ltd. "Nitesh has had an excellent track record as COO of GlobalLogic and I am confident that he will be able to maintain the high momentum of growth in the future. We are pleased to be working with a leader of his caliber to deliver new value through innovation, Green, and Digital solutions for our customers around the world."
“With GlobalLogic becoming a part of the Hitachi Family, Hitachi’s digital capability has expanded tremendously,” said Mr. Tokunaga. “I would like to thank Shashank for his capable leadership and look forward to his contributions as Chairman of the Board. Going forward, under Nitesh's leadership, I expect GlobalLogic to continue creating synergies with Hitachi Digital and other Hitachi Group companies, and to dramatically expand the digital business through DX support for customers worldwide.”
About GlobalLogic Inc.
GlobalLogic (www.globallogic.com
) is a leader in digital engineering. We help brands across the globe design and build innovative products, platforms, and digital experiences for the modern world. By integrating experience design, complex engineering, and data expertise – we help our clients imagine what’s possible and accelerate their transition into tomorrow’s digital businesses. Headquartered in Silicon Valley, GlobalLogic operates design studios and engineering centers around the world, extending our deep expertise to customers in the automotive, communications, financial services, healthcare and life sciences, manufacturing, media and entertainment, semiconductor, and technology industries. GlobalLogic is a Hitachi Group Company operating under Hitachi, Ltd.
(TSE: 6501), which contributes to a sustainable society with a higher quality of life by driving innovation through data and technology as the Social Innovation Business.
About Hitachi, Ltd.
Hitachi drives Social Innovation Business, creating a sustainable society with data and technology. We will solve customers' and society's challenges with Lumada solutions leveraging IT, OT (Operational Technology) and products, under the business structure of Digital Systems & Services, Green Energy & Mobility, Connective Industries and Automotive Systems. Driven by green, digital, and innovation, we aim for growth through collaboration with our customers. The company’s consolidated revenues for fiscal year 2021 (ended March 31, 2022) totaled 10,264.6 billion yen ($84,136 million USD), with 853 consolidated subsidiaries and approximately 370,000 employees worldwide. For more information on Hitachi, please visit the company's website at https://www.hitachi.com
.
GlobalLogic is a trademark of GlobalLogic. All other brands, products or service names are or may be trademarks or service marks of their respective owners.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220803006014/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Doubtless Pet Care Launches to Provide Peace of Mind to Pet Parents and Help Their Pets Live Happier, Healthier Lives29.6.2026 10:15:00 CEST | Press release
Doubtless combines industry-leading pet insurance with innovative care solutions, protecting more than 6 million pets across 10 global markets Doubtless launches today with the goal of helping more pet parents across the world access quality care for the pets they love. The company brings together a leading global portfolio of pet insurance brands with a growing range of connected solutions designed to support pet parents at every stage of their pet’s life. With over 4,000 employees, Doubtless insures 6 million pets across 10 markets in North America, Europe and the United Kingdom. “Uncertainty about the financial commitments associated with having a pet should never keep families from experiencing the joy of a life with pets,” said Dirk Beeckman, CEO of Doubtless. “By harnessing the power of our international footprint, we are building on our leadership in pet insurance to create a global suite of solutions for pet parents, veterinarians and industry partners that makes pet care easie
Samsung Bioepis Announces Positive Preliminary Phase 1 and Phase 3 Data for SB27, a Proposed Biosimilar to Keytruda (Pembrolizumab)29.6.2026 09:19:00 CEST | Press release
Phase 1 study demonstrated pharmacokinetic (PK) equivalence between SB27 and Keytruda; Phase 3 study demonstrated equivalent objective response rate (ORR) at Week 24Phase 1 and Phase 3 studies expected to be completed within 2026 Samsung Bioepis Co., Ltd. announced today that the Phase 1 and Phase 3 studies on SB27, a proposed biosimilar to Keytruda1 (pembrolizumab), have met their primary endpoints. “We are excited to announce preliminary results from the Phase 1 and Phase 3 studies for SB27, our pembrolizumab biosimilar candidate. These topline positive results reinforce our scientific expertise and leadership in biosimilar development,” said Donghoon Shin, Executive Vice President and Head of Clinical Sciences Division at Samsung Bioepis. “We are on track to complete both Phase 1 and Phase 3 studies within this year. Leveraging our robust quality management system, we remain committed to advancing our biosimilar portfolio to broaden access to life-saving biologic medicines for patie
IQM Named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment29.6.2026 09:00:00 CEST | Press release
IQM today announced it has been named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260629748732/en/ IQM named a major player in the IDC MarketScape IQM believes this recognition comes as institutions worldwide move quantum computing out of shared cloud access and into infrastructure they own and operate themselves. IQM calls this Production Quantum: full-stack, open-architecture superconducting systems deployed on premises, inside customers' own data centers and HPC environments, where organizations own the hardware, build internal expertise, and run quantum processors alongside their existing classical infrastructure. According to the IDC MarketScape, "For institutions building long-term quantum programs, this means the workflows and intellectual property developed on IQM hardware remain portable." The report further advises: "Consi
Zambon Announces Positive CHMP Opinion for Hopledo® (IPX203) for Adults with Parkinson’s Disease and Moderate to Severe Motor Fluctuations29.6.2026 09:00:00 CEST | Press release
Positive CHMP opinion is based on data from the Phase 3 RISE-PD trial, which demonstrated significantly more “Good ON” time with fewer daily doses compared with immediate-release levodopa/carbidopa More than one million people are living with Parkinson’s disease in the European Union, and over 80% experience motor fluctuations during the course of their disease, highlighting the need for additional treatment options Hopledo® contains a unique formulation combining immediate-release granules and extended-release pellets, providing both a rapid onset of action and a longer duration of effect, sustaining the levodopa therapeutic effect for a longer period of time If approved, Zambon expects to make Hopledo® progressively available to patients with Parkinson’s disease across Europe starting October 2026 Zambon today announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of a marketing authorization by the European M
Enhertu® Approved in the EU as First Tumor Agnostic HER2 Directed Therapy and Antibody Drug Conjugate for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors29.6.2026 08:30:00 CEST | Press release
Approval based on three phase 2 trials of Daiichi Sankyo and AstraZeneca’s Enhertu that demonstrated clinically meaningful responses across a broad range of tumors Enhertu now approved for six indications in the EU Enhertu® (trastuzumab deruxtecan) has been approved in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinion of the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from subgroups of patients with HER2 positive (IHC 3+) tumors across thr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom